基本信息
浏览量:53
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Dr. Al-Dewik is currently a Director of Translational and Precision Medicine Research, Principal Investigator at Hamad Medical Corporation (HMC), and A/Professor in Human Genetics, Genomic and Precision Medicine Program, College of Health and Life Sciences, Hamad Bin Khalifa University (HBKU) in the State of Qatar.
Dr. Al-Dewik was awarded his Ph.D. in Biomedical Sciences from Kingston University and St George’s Medical School, London, United Kingdom (UK) in Molecular Biology and Human Genetics. He received his postgraduate award in Cancer Biology & Therapeutics (CBT) program from Harvard Medical School (HMS), USA. He is licensed by the Ministry of Public Health in Qatar as a Clinical Scientist and by the Ministry of Health in Jordan as a Laboratory medicine specialist. Dr. Al-Dewik actively participates in several teaching modules at Qatar University (QU) and Hamad Bin Khalifa University (HBKU) and successfully supervises several Ph.D., MSc, and BSc students to their degrees. Dr. Al-Dewik is a member of several prestigious international professional bodies such as the Society for the Study of Inborn Errors of Metabolism (SSIEM), European Hematology Association (EHA), and the American Society of Hematology (ASH).
Dr. Al-Dewik is successfully running several research grants funded by different funding bodies such as the Qatar National Research Fund QNRF, HMC. The team secured up to USD$ $9M between 2008 - 2023. Dr. Al-Dewik was awarded an innovation fund from Qatar Science and Technology Park (QSTP) to develop an absolute quantification molecular kit to measure a new biomarker and monitor Minimal Residual Disease (MRD). As a key principal investigator in the funded grants, he works with several international teams on translational molecular genetics. His research activities address high-priority inherited genetic disorders such as Homocystinuria, White Matter Diseases (WMDs), Leukemia, and Cancer ] as well as Clinical trials for Mucopolysaccharidosis type IV (MPS type IV) and Spinal Muscular Atrophy. Dr. Al-Dewik’s approach is multidisciplinary and collaborative in nature. His research interests include identifying the underlying genetic factors and signaling pathways involved in oncological diseases, novel biomarkers discovery, and studying the effects of founder mutations in the Qatari population for genetic disorders and leukemia. He contributes to the body of published knowledge in metabolic, genetics, and cancer with over 50 articles in peer-reviewed journals, book chapters, and abstracts
研究兴趣
论文共 87 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Jesni Vazhiyelethil,Fathima Minisha, Sawsan Al Obaidly,Mai AlQubaisi,Husam Salama,Najah Ali,Najat Khenyab,Suruchi Mohan, Abdul Rouf Pallivalappil,Nader Al-Dewik,Hilal Al Rifai,Tom Farrell
Qatar medical journalno. 1 (2024): 2-2
Scientific Reportsno. 1 (2024): 1-16
INFLUENZA AND OTHER RESPIRATORY VIRUSESno. 5 (2024): 118492-e13290
Shameena Ajmal,Thomas Farrell,Fathima Minisha, Sawsan Al Obaidly,Mai AlQubaisi,Najat Khenyab,Najah Ali,Husam Salama, Abdul Rouf Pallivalappil,Nader Al Dewik,Hilal Al Rifai
Qatar medical journalno. 1 (2024): 3-3
Fouad Chaalan,Fathima Minisha, Zehra Zaidi, Alaa Babekar, Huda Abullah Hussain Saleh, Zeena Saeed Bu Shurbak, Mariam Al Baloushi, Alaa Alnaama, Husham Ahmed,Isaac Babarinsa,Nader Al Dewik,Abdulrouf Pallivalapila,
BMC Pregnancy and Childbirthno. 1 (2024): 1-12
BIOMEDICINESno. 1 (2024): 217
BalaSubramani Gattu Linga,Sawsan G A A Mohammed,Thomas Farrell,Hilal Al Rifai,Nader Al-Dewik,M Walid Qoronfleh
Cancersno. 11 (2024): 2017
加载更多
作者统计
#Papers: 92
#Citation: 986
H-Index: 18
G-Index: 28
Sociability: 6
Diversity: 0
Activity: 2
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn